Benjamin Edwards Inc. Sells 11,105 Shares of Zoetis Inc. $ZTS

Key Points

• Benjamin Edwards Inc. reduced its stake in Zoetis by 4.7%, selling 11,105 shares and now holds 224,022 shares valued at about $28.19 million (≈0.05% of the company).
• Analyst sentiment is mixed with a MarketBeat consensus rating of "Hold" and an average price target of $151.75 after several firms cut targets and downgraded the stock.
• Zoetis beat Q expectations (EPS $1.48 vs. $1.40; revenue $2.39B), set FY2026 guidance of 7.00–7.10 EPS, and declared a quarterly dividend of $0.53 (annual yield ~1.9%).

Benjamin Edwards Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 224,022 shares of the company's stock after selling 11,105 shares during the quarter. Benjamin Edwards Inc. owned approximately 0.05% of Zoetis worth $28,187,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. CIBC Asset Management Inc raised its holdings in shares of Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company's stock worth $36,745,000 after purchasing an additional 10,434 shares during the period. Nordea Investment Management AB raised its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Seilern Investment Management Ltd raised its holdings in shares of Zoetis by 361.2% in the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company's stock worth $41,957,000 after purchasing an additional 261,155 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company's stock worth $205,290,000 after purchasing an additional 935,432 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company's stock worth $43,235,000 after purchasing an additional 18,040 shares during the period. Institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of research reports. UBS Group lowered their price target on shares of Zoetis from $136.00 to $130.00 and set a "neutral" rating on the stock in a report on Tuesday, April 28th. Piper Sandler reaffirmed a "neutral" rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reaffirmed a "buy" rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Weiss Ratings cut shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Hold" and an average price target of $151.75.

Zoetis Trading Down 0.7%

Shares of ZTS stock opened at $114.22 on Friday. The company's fifty day simple moving average is $119.93 and its two-hundred day simple moving average is $124.67. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $112.97 and a 1 year high of $172.23. The stock has a market capitalization of $48.05 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. During the same quarter in the previous year, the firm posted $1.40 EPS. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts anticipate that Zoetis Inc. will post 7.01 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. Zoetis's payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.